ENTRY       D10813                      Drug
NAME        Cerliponase alfa (USAN/INN);
            Cerliponase alfa (genetical recombination) (JAN);
            Brineura (TN)
PRODUCT     BRINEURA (BioMarin Pharmaceutical)
SEQUENCE    SYSPEPDQRR TLPPGWVSLG RADPEEELSL TFALRQQNVE RLSELVQAVS DPSSPQYGKY
            LTLENVADLV RPSPLTLHTV QKWLLAAGAQ KCHSVITQDF LTCWLSIRQA ELLLPGAEFH
            HYVGGPTETH VVRSPHPYQL PQALAPHVDF VGGLHRFPPT SSLRQRPEPQ VTGTVGLHLG
            VTPSVIRKRY NLTSQDVGSG TSNNSQACAQ FLEQYFHDSD LAQFMRLFGG NFAHQASVAR
            VVGQQGRGRA GIEASLDVQY LMSAGANIST WVYSSPGRHE GQEPFLQWLM LLSNESALPH
            VHTVSYGDDE DSLSSAYIQR VNTELMKAAA RGLTLLFASG DSGAGCWSVS GRHQFRPTFP
            ASSPYVTTVG GTSFQEPFLI TNEIVDYISG GGFSNVFPRP SYQEEAVTKF LSSSPHLPPS
            SYFNASGRAY PDVAALSDGY WVVSNRVPIP WVSGTSASTP VFGGILSLIN EHRILSGRPP
            LGFLNPRLYQ QHGAGLFDVT RGCHESCLDE EVEGQGFCSG PGWDPVTGWG TPNFPALLKT
            LLNP
            (Disulfide bridge: 92-103, 346-507, 503-518)
  TYPE      Peptide
REMARK      Therapeutic category: 3959
            ATC code: A16AB17
            Product: D10813<JP/US>
EFFICACY    Lysosomal storage disease treatment, Enzyme replacement (tripeptidyl peptidase)
  DISEASE   Neuronal ceroid lipofuscinosis type 2 [DS:H00149]
  TYPE      Enzyme replacement therapy product
TARGET      TPP1* [HSA_VAR:1200v1] [HSA:1200] [KO:K01279]
  PATHWAY   hsa04142(1200)  Lysosome
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
               A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
                A16AB Enzymes
                 A16AB17 Cerliponase alfa
                  D10813  Cerliponase alfa (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Cerliponase alfa
               D10813  Cerliponase alfa (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               395  Enzyme preparations
                3959  Others
                 D10813  Cerliponase alfa (USAN/INN); Cerliponase alfa (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Peptidyl-peptidases
                TPP1* [HSA_VAR:1200v1]
                 D10813  Cerliponase alfa (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10813
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10813
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10813
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10813
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D10813
DBLINKS     CAS: 151662-36-1
            PubChem: 319902614
///
